Voxelotor - Global Blood Therapeutics

Drug Profile

Voxelotor - Global Blood Therapeutics

Alternative Names: GBT-440; GTx-011

Latest Information Update: 08 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Global Blood Therapeutics
  • Class Antianaemics; Small molecules
  • Mechanism of Action Sickle haemoglobin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Phase I Hypoxia; Liver disorders
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 06 Mar 2018 Global Blood Therapeutics plans to launch voxelotor for Sickle cell disease
  • 16 Jan 2018 Global Blood Therapeutics plans an open-label extension phase III trial for Sickle cell disease in the UK, Canada, Egypt, France, Ghana, Italy, Jamaica, Kenya, Lebanon, Netherlands, Nigeria, Oman, Turkey, USA in January 2018 (EudraCT2017-004045-25)
  • 09 Jan 2018 Voxelotor- Global Blood Therapeutics receives Breakthrough Therapy status for Sickle cell anaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top